B cell depletion

$CBPO secures $7.5M milestone from Boehringer Ingelheim partnership, with $337.5M upside potential as lead compound advances to optimization.

IMN market expected to grow nearly 8x from $130M in 2025 to $1B by 2036, driven by novel therapies addressing unmet treatment needs.

Galapagos and Gilead plan to jointly develop an Ouro T cell engager for autoimmune diseases, splitting acquisition costs while Galapagos leads development and Gilead commercializes, freeing $500M in Galapagos cash.